John P Gleeson
John P Gleeson
Senior Scientist - Biopharmaceutics, Merck
Verified email at merck.com
Title
Cited by
Cited by
Year
Enhanced utilization of induced pluripotent stem cell-derived human intestinal organoids using microengineered Chips
MJ Workman, JP Gleeson, EJ Troisi, HQ Estrada, SJ Kerns, CD Hinojosa, ...
Cellular and Molecular Gastroenterology and Hepatology, 2017
1132017
Safety concerns over the use of intestinal permeation enhancers: A mini-review
F McCartney, JP Gleeson, DJ Brayden
Tissue barriers 4 (2), e1176822, 2016
792016
Oral delivery strategies for nutraceuticals: Delivery vehicles and absorption enhancers
JP Gleeson, SM Ryan, DJ Brayden
Trends in Food Science & Technology 53, 90-101, 2016
762016
A head-to-head multi-parametric high content analysis of a series of medium chain fatty acid intestinal permeation enhancers in Caco-2 cells
DJ Brayden, J Gleeson, EG Walsh
European journal of pharmaceutics and biopharmaceutics 88 (3), 830-839, 2014
622014
Stability, toxicity and intestinal permeation enhancement of two food-derived antihypertensive tripeptides, Ile-Pro-Pro and Leu-Lys-Pro
JP Gleeson, J Heade, SM Ryan, DJ Brayden
Peptides 71, 1-7, 2015
372015
Evaluation of PepT1 transport of food-derived antihypertensive peptides, Ile-Pro-Pro and Leu-Lys-Pro using in vitro, ex vivo and in vivo transport models
JP Gleeson, DJ Brayden, SM Ryan
European Journal of Pharmaceutics and Biopharmaceutics 115, 276-284, 2017
262017
Excess growth hormone suppresses DNA damage repair in epithelial cells
V Chesnokova, S Zonis, R Barrett, H Kameda, K Wawrowsky, ...
JCI insight 4 (3), 2019
162019
Diet, food components and the intestinal barrier
JP Gleeson
Nutrition Bulletin 42 (2), 123-131, 2017
152017
Sodium caprate enables the blood pressure-lowering effect of Ile-Pro-Pro and Leu-Lys-Pro in spontaneously hypertensive rats by indirectly overcoming PepT1 inhibition
JP Gleeson, JM Frías, SM Ryan, DJ Brayden
European Journal of Pharmaceutics and Biopharmaceutics 128, 179-187, 2018
112018
Growth hormone induces colon DNA damage independent of IGF-1
V Chesnokova, S Zonis, RJ Barrett, JP Gleeson, S Melmed
Endocrinology 160 (6), 1439-1447, 2019
92019
Striving towards the perfect in vitro oral drug absorption model
JP Gleeson, F McCartney
Trends in pharmacological sciences 40 (10), 720-724, 2019
82019
Development of physiologically responsive human iPSC-derived intestinal epithelium to study barrier dysfunction in IBD
JP Gleeson, HQ Estrada, M Yamashita, CN Svendsen, SR Targan, ...
International journal of molecular sciences 21 (4), 1438, 2020
72020
The enhanced intestinal permeability of infant mice enables oral protein and macromolecular absorption without delivery technology
JP Gleeson, KC Fein, N Chaudhary, R Doerfler, AN Newby, ...
International journal of pharmaceutics 593, 120120, 2021
32021
From farm to pharmacy: strawberry-enabled oral delivery of protein drugs
NG Lamson, KC Fein, JP Gleeson, S Xian, A Newby, N Chaudhary, ...
bioRxiv, 2020
22020
Oral delivery of peptide therapeutics in infants: Challenges and opportunities
JP Gleeson, KC Fein, KA Whitehead
Advanced drug delivery reviews, 2021
12021
The system can't perform the operation now. Try again later.
Articles 1–15